NASDAQ · Financial Statements

Denali Therapeutics Inc. (DNLI) Financial Statements

$18.41 NASDAQ: DNLI Market Cap $2.94B

Denali Therapeutics Inc. most recently reported annual revenue of $0, a net loss of $513.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Denali Therapeutics Inc.: net profit was positive in 1 of 10 reported years; operating margin moved from -35.9% to -59.5%, a shift of -23.6 percentage points; the most recent year shows a net loss of $513.0M.

Income Statement — 10 Years (USD millions)

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	$0	$0	$129.0M	$27.0M	$336.0M	$49.0M	$108.0M	$331.0M	$0	$0
Operating Expenses	$87.0M	$90.0M	$176.0M	$240.0M	$273.0M	$344.0M	$449.0M	$527.0M	$487.0M	$555.0M
Operating Profit	$-87.0M	$-90.0M	$-46.0M	$-213.0M	$63.0M	$-296.0M	$-341.0M	$-197.0M	$-487.0M	$-555.0M
Operating Margin	0.0%	0.0%	-35.9%	-799.1%	18.7%	-607.8%	-314.2%	-59.5%	0.0%	0.0%
Other Income	$1.0M	$2.0M	$10.0M	$15.0M	$9.0M	$5.0M	$15.0M	$52.0M	$65.0M	$43.0M
Interest	$0	$2.0M	$0	$0	$0	$0	$0	$0	$0	$0
Depreciation	$1.0M	$3.0M	$7.0M	$8.0M	$9.0M	$9.0M	$10.0M	$17.0M	$9.0M	$15.0M
Profit Before Tax	$-87.0M	$-88.0M	$-36.0M	$-198.0M	$72.0M	$-291.0M	$-326.0M	$-145.0M	$-423.0M	$-512.0M
Tax	$0	$0	$0	$180,000	$1.1M	$200,000	$-10,000	$-20,000	$-20,000	$-20,000
Net Profit	$-87.0M	$-88.0M	$-36.0M	$-198.0M	$71.0M	$-291.0M	$-326.0M	$-145.0M	$-423.0M	$-513.0M
EPS	$-13.49	$-5.89	$-0.39	$-2.07	$0.63	$-2.39	$-2.60	$-1.06	$-2.57	$-2.97
Dividend Payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

Metric	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
Revenue	$1.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$4.0M
Operating Expenses	$115.0M	$133.0M	$118.0M	$117.0M	$123.0M	$130.0M	$146.0M	$135.0M	$137.0M	$137.0M	$137.0M	$134.0M
Operating Profit	$-114.0M	$-133.0M	$-118.0M	$-117.0M	$-123.0M	$-130.0M	$-146.0M	$-135.0M	$-137.0M	$-137.0M	$-137.0M	$-131.0M
Operating Margin	-8981.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-3622.1%
Interest	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Profit Before Tax	$-99.0M	$-119.0M	$-102.0M	$-99.0M	$-107.0M	$-115.0M	$-133.0M	$-124.0M	$-127.0M	$-128.0M	$-128.0M	$-128.0M
Tax	$0	$-30,000	$0	$0	$0	$-60,000	$0	$0	$0	$-80,000	$0	$0
Net Profit	$-99.0M	$-119.0M	$-102.0M	$-99.0M	$-107.0M	$-115.0M	$-133.0M	$-124.0M	$-127.0M	$-129.0M	$-128.0M	$-128.0M
EPS	$-0.72	$-0.86	$-0.68	$-0.59	$-0.63	$-0.67	$-0.78	$-0.72	$-0.74	$-0.73	$-0.69	$-0.68

Over the 10 years reported for Denali Therapeutics Inc., cash stood at $205.0M in the latest year, shareholders' equity was $2.0M, current assets covered current liabilities 9.19 times.

Balance Sheet — 10 Years (USD millions)

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	$271.0M	$487.0M	$662.0M	$553.0M	$1.6B	$1.4B	$1.5B	$1.2B	$1.4B	$1.1B
Current Assets	$182.0M	$410.0M	$481.0M	$430.0M	$1.5B	$897.0M	$1.4B	$1.1B	$864.0M	$901.0M
Cash	$40.0M	$218.0M	$77.0M	$79.0M	$507.0M	$293.0M	$218.0M	$127.0M	$175.0M	$205.0M
Inventory	$0	$0	$-9.0M	$0	$0	$0	$0	$0	$0	$0
Receivables	$0	$0	$9.0M	$0	$0	$1.0M	$9.0M	$3.0M	$2.0M	$2.0M
Fixed Assets	$15.0M	$15.0M	$25.0M	$81.0M	$73.0M	$70.0M	$75.0M	$72.0M	$126.0M	$120.0M
Capital Work in Progress	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Investments	$212.0M	$249.0M	$535.0M	$376.0M	$997.0M	$997.0M	$1.1B	$907.0M	$1.0B	$761.0M
Other Assets	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$17.0M	$21.0M	$115.0M	$158.0M	$454.0M	$442.0M	$418.0M	$123.0M	$144.0M	$131.0M
Current Liabilities	$9.0M	$14.0M	$33.0M	$45.0M	$72.0M	$378.0M	$364.0M	$78.0M	$102.0M	$98.0M
Borrowings	$0	$0	$0	$73.0M	$69.0M	$64.0M	$60.0M	$52.0M	$49.0M	$37.0M
Other Liabilities	$17.0M	$21.0M	$115.0M	$86.0M	$385.0M	$378.0M	$357.0M	$71.0M	$96.0M	$94.0M
Equity	$3.0M	$1.0M	$1.0M	$1.0M	$2.0M	$2.0M	$2.0M	$2.0M	$2.0M	$2.0M
Reserves	$255.0M	$466.0M	$547.0M	$395.0M	$1.2B	$962.0M	$1.0B	$1.0B	$1.2B	$1.0B

For Denali Therapeutics Inc., operating cash flow was positive in 2 of 10 reported years; free cash flow in the latest year was negative at $422.0M; free cash flow was positive in 2 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating Cash Flow	$-72.0M	$-77.0M	$50.0M	$-152.0M	$416.0M	$-211.0M	$-245.0M	$-358.0M	$-348.0M	$-413.0M
Investing Cash Flow	$-438.0M	$-82.0M	$-575.0M	$130.0M	$-626.0M	$-30.0M	$-159.0M	$236.0M	$-105.0M	$246.0M
Financing Cash Flow	$0	$1.0M	$3.0M	$6.0M	$21.0M	$0	$14.0M	$0	$17.0M	$0
Net Cash Flow	$9.0M	$179.0M	$-140.0M	$2.0M	$428.0M	$-214.0M	$-75.0M	$-91.0M	$48.0M	$32.0M
Free Cash Flow	$-78.0M	$-80.0M	$47.0M	$-169.0M	$413.0M	$-220.0M	$-263.0M	$-371.0M	$-364.0M	$-422.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	4.11
EV / EBITDA	-6.03
FCF Yield	-13.78%
Quick Ratio	8.32
Interest Coverage	—
Return 1Y	53.35%
Return 3Y	4.62%
Return 5Y	-53.51%

Denali Therapeutics Inc. (DNLI) financials — frequently asked questions

What is Denali Therapeutics Inc.'s annual revenue?

Denali Therapeutics Inc. (DNLI) reported annual revenue of $0 in its most recent fiscal year.

What is Denali Therapeutics Inc.'s net profit?

Denali Therapeutics Inc. (DNLI) reported a net loss of $513.0M in its most recent fiscal year.

What is DNLI EV/EBITDA?

Denali Therapeutics Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -6.03. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

DNLI Overview DNLI Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.